Clinical trials: Neuroepithelial Tumor
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body.
- Conditions
- Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma
- Trial name
- NCT06176989
- Testing
- Enasidenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Astrocytoma
IDH1 and OCT4 in High Grade Astrocytoma
observation of IDH1 and OCT4 markers level and high grade astrocytoma patients prognosis after excision.
- Trial name
- NCT06214689
- Testing
- biomarkers analysis
- Where
- Egypt
- Volunteers
- 35 people
- Sponsor
- Assiut University
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Glioblastoma
Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
For patients with progressive or recurrent glioblastoma there is no standard therapy. One strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done by 2 regimens.
- Trial name
- DIRECTOR (NCT00941460)
- Testing
- Temozolomide in both arms
- Where
- 16 sites in Austria, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Prof. Dr. Wolfgang Wick
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Glioblastoma, Glioblastoma Multiforme
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper.
- Trial name
- NCT03363659
- Testing
- Disulfiram, Copper gluconate, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Brain Tumor, Central Nervous System Tumor
High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
RATIONALE: Drugs used in chemotherapy, such as carboplatin, thiotepa, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00078988
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 59 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- Children's Oncology Group
Glioblastoma, Recurrent Glioblastoma
Niraparib/TTFields in GBM
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Trial name
- NCT04221503
- Testing
- Niraparib, Optune, Planned surgical resection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Malignant Glioma
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent).
- Conditions
- Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
- Trial name
- NCT05045027
- Testing
- Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma
TH-302 in Combination With Bevacizumab for Glioblastoma
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
- Trial name
- NCT02342379
- Testing
- Bevacizumab, TH-302
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioblastoma, Mismatch Repair Deficiency
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma with Mismatch Repair Deficiency.
- Trial name
- NCT07385846
- Testing
- Pembrolizumab, Navifus Focused Ultrasound Sonification
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jennifer Leddon
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IDH-mutant Grade 2 or 3 Astrocytoma
Vorasidenib Maintenance for IDH Mutant Astrocytoma
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3…
- Trial name
- VIGOR (NCT06809322)
- Testing
- Vorasidenib
- Where
- 59 sites in Australia, Austria and 10 more
- Volunteers
- 468 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Retinoblastoma
SPT Screening in Irradiated Hereditary Retinoblastoma Survivors
Rationale: Hereditary retinoblastoma survivors have an increased risk to develop second primary tumors (SPT) at a later age (with the highest risk in their teens), especially when they have been irradiated for retinoblastoma.
- Trial name
- NCT02329002
- Testing
- Magnetic resonance imaging
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Amsterdam UMC, location VUmc
Brain Neoplasms, Glioma
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site.
- Conditions
- Brain Neoplasms, Glioma, Medulloblastoma
- Trial name
- NCT00001502
- Testing
- RMP-7 and carboplatin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801.
- Trial name
- NCT05222802
- Testing
- ERAS-801
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Katmai Pharmaceuticals Inc.
Malignant Gliomas, Radiotherapy
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
The Stupp protocol is the standard treatment of glioblastoma multiform (GBM) which prognosis remains poor. The non-dividing nature of normal brain cells provides an opportunity to enhance the therapeutic ratio by combining…
- Conditions
- Malignant Gliomas, Radiotherapy, PARP Inhibitor
- Trial name
- OLA-TMZ-RTE-01 (NCT03212742)
- Testing
- Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)
- Where
- 15 sites in France
- Volunteers
- 91 people
- Sponsor
- Centre Francois Baclesse
Diffuse Intrinsic Pontine Glioma
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse pontine gliomas are tumors on the pons portion of the brainstem. Their peak incidence is in children between 5 and 10 years old. Their location makes surgical resection impossible.
- Trial name
- NCT00036569
- Testing
- adjuvant therapy, pegylated interferon alfa
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Background: The brain is separated from the rest of the blood stream by the blood-brain barrier. This is like a filter that protects the brain. But is also a challenge when medicines need to get into the brain.
- Conditions
- Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme, Giant Cell Glioblastoma, Glioma
- Trial name
- NCT03027388
- Testing
- LB-100
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)